• 1. Atrial Fibrillation and Valvular Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, 101100, P. R. China;
  • 2. Department of Cardiac Surgery, Chongqing Academy of Medical Sciences/Chongqing People's Hospital, Chongqing University, Chongqing, 401147, P. R. China;
  • 3. Nanchong Hospital of Beijing Anzhen Hospital, Capital Medical University/Nanchong Central Hospital, Nanchong, 637000, Sichuan, P. R. China;
  • 4. Structural Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100037, P. R. China;
  • 5. Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China;
  • 6. Department of Cardiovascular Surgery, Xijing Hospital, Air Force Military Medical University, Xi'an, 710032, P. R. China;
  • 7. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China;
  • 8. Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100037, P. R. China;
  • 9. Cardiac Valvular Surgery Center, Shanghai No.4 People's Hospital, Tongji University, Shanghai, 200000, P. R. China;
  • 10. Department of Cardiac Surgery, Second Xiangya Hospital, Central South University, Changsha, 410000, P. R. China;
ZHANG Haibo, Email: zhanghb2318@163.com
Export PDF Favorites Scan Get Citation

The increasing use of bioprosthetic aortic valves, together with population aging, has led to a growing clinical need for reintervention after bioprosthetic valve destruction in China. For elderly patients at high surgical risk or with multiple organ dysfunction, transcatheter valve-in-valve (ViV) therapy provides a crucial minimally invasive alternative to redo surgical valve replacement. However, the ViV procedure differs substantially from redo surgical valve replacement in its workflow, patient selection, and risk profile, necessitating standardized guidance. Therefore, a multidisciplinary group of experts from multiple cardiac centers in China has developed these recommendations based on current evidence and clinical experience. The goal is to guide individualized treatment for patients with failed aortic bioprostheses and to promote the standardized implementation of ViV therapy in clinical practice.

Copyright ? the editorial department of Chinese Journal of Clinical Thoracic and Cardiovascular Surgery of West China Medical Publisher. All rights reserved